Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer

Autor: Yuval Mizrakli, Amos Douvdevani, Maia Rosenthal, Victor Novack, Samuel Ariad, Ravit Agassi, Reut Riff, Shaked Yarza, David Czeiger, Irena Lazarev, Michal Peled
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Receptor
ErbB-2
medicine.medical_treatment
lcsh:Medicine
Circulating Tumor DNA
Prognostic markers
Breast cancer
0302 clinical medicine
Medicine
Prospective Studies
Prospective cohort study
lcsh:Science
Aged
80 and over
Multidisciplinary
medicine.diagnostic_test
Middle Aged
Prognosis
Combined Modality Therapy
Tumor Burden
Receptors
Estrogen
Cell-free fetal DNA
Female
Receptors
Progesterone
Cell-Free Nucleic Acids
Mammography
Adult
medicine.medical_specialty
Adolescent
Breast Neoplasms
Article
Young Adult
03 medical and health sciences
Internal medicine
Biopsy
Biomarkers
Tumor
Humans
In patient
Aged
Chemotherapy
business.industry
lcsh:R
Cancer
medicine.disease
030104 developmental biology
lcsh:Q
business
Biomarkers
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
ISSN: 2045-2322
Popis: Mammography has a crucial role in the detection of breast cancer (BC), yet it is not limitation-free. We hypothesized that the combination of mammography and cell-free DNA (cfDNA) levels may better discriminate patients with cancer. This prospective study included 259 participants suspected with BC before biopsy. Blood samples were taken before biopsy and from some patients during and at the end of treatment. cfDNA blood levels were measured using our simple fluorescent assay. The primary outcome was the pathologic diagnosis of BC, and the secondary aims were to correlate cfDNA to severity, response to treatments, and outcome. Median cfDNA blood levels were similar in patients with positive and negative biopsy: 577 vs. 564 ng/ml (p = 0.98). A significant decrease in cfDNA blood level was noted after the following treatments: surgery, surgery and radiation, neo-adjuvant chemotherapy and surgery, and at the end of all treatments. To conclude, the cfDNA level could not be used in suspected patients to discriminate BC. Reduction of tumor burden by surgery and chemotherapy is associated with reduction of cfDNA levels. In a minority of patients, an increase in post-treatment cfDNA blood level may indicate the presence of a residual tumor and higher risk. Further outcome assessment for a longer period is suggested.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje